Inhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.
The NF-κB pathway performs pivotal roles in diverse physiological processes such as immunity, inflammation, proliferation, and apoptosis. NF-κB is kept inactive in the cytoplasm through association with inhibitors (IκB), and translocates to the nucleus to activate its target genes after the IκBs are phosphorylated and degraded. Here, we demonstrate that loss of function of SHANK-associated RH domain interacting protein (SHARPIN) leads to activation of NF-κB signaling in skin, resulting in the development of an idiopathic hypereosinophilic syndrome (IHES) with eosinophilic dermatitis in C57BL/KaLawRij-Sharpin(cpdm)/RijSunJ mice, and clonal expansion of B-1 B cells and CD3(+)CD4(-)CD8(-) T cells. Transcription profiling in skin revealed constitutive activation of classical NF-κB pathways, predominantly by overexpressed members of IL1 family. Compound-null mutants for both the IL1 receptor accessory protein (Il1rap(tm1Roml)) and SHARPIN (Sharpin(cpdm)) resulted in mice having decreased skin disease severity. Inhibition of IκBA degradation by the proteasome inhibitor bortezomib alleviated the dermatitis in Sharpin(cpdm) mice. These results indicate that absence of SHARPIN causes IHES with eosinophilic dermatitis by NF-κB activation, and bortezomib may be an effective treatment for skin problems of IHES.
Liang
Yanhua
Y
The Jackson Laboratory, Bar Harbor, Maine, USA.
Seymour
Rosemarie E
RE
Sundberg
John P
JP
D000818:Animals; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D003872:Dermatitis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004802:Eosinophilia / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D020869:Gene Expression Profiling; D007150:Immunohistochemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D052002:NF-kappa B p50 Subunit / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000378:metabolism; D010641:Phenotype; D010766:Phosphorylation / Q000502:physiology; D011480:Protease Inhibitors / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors* / Q000378:metabolism
D001897:Boronic Acids; D052002:NF-kappa B p50 Subunit; D009419:Nerve Tissue Proteins; D011480:Protease Inhibitors; D011719:Pyrazines; D051996:Transcription Factor RelA; C425287:sharpin; D000069286:Bortezomib
N Engl J Med. 1994 Feb 24;330(8):535-8
8302319
Oncogene. 2006 Oct 30;25(51):6680-4
17072321
N Engl J Med. 2003 Dec 11;349(24):2334-9
14668459
Oncology. 2006;70(6):474-82
17283449
Semin Dermatol. 1995 Jun;14(2):122-8
7640191
Cancer Res. 1999 Jun 1;59(11):2615-22
10363983
Genes Dev. 2004 Sep 15;18(18):2195-224
15371334
Exp Dermatol. 2000 Oct;9(5):351-8
11016856
Cancer Treat Res. 2008;142:69-106
18283783
Am J Pathol. 1996 Mar;148(3):941-50
8774148
Clin Exp Immunol. 2001 Mar;123(3):505-10
11298140
Annu Rev Immunol. 2009;27:519-50
19302047
Clin Exp Immunol. 2007 Aug;149(2):217-25
17590166
J Cell Biol. 2000 May 29;149(5):999-1004
10831603
N Engl J Med. 1998 May 28;338(22):1592-600
9603798
Immunobiology. 2010 Apr;215(4):264-74
19581018
Ultrastruct Pathol. 1995 Mar-Apr;19(2):107-11
7792947
Genes Immun. 2007 Jul;8(5):416-21
17538631
N Engl J Med. 2008 Jun 26;358(26):2838-9; author reply 2839-40
18579821
Curr Opin Hematol. 2007 Jan;14(1):37-42
17133098
J Exp Med. 2007 Oct 29;204(11):2603-14
17908936
Exp Dermatol. 2010 Mar;19(3):252-8
19650867
PLoS One. 2007 Oct 03;2(10):e997
17912374
Blood. 2008 Sep 15;112(6):2500-7
18539901
N Engl J Med. 1999 Oct 7;341(15):1112-20
10511609
J Immunol. 1999 Apr 1;162(7):3890-6
10201907
CA Cancer J Clin. 2009 Mar-Apr;59(2):111-37
19278961
J Gastroenterol Hepatol. 2003 Jun;18(6):712-8
12753155
Curr Opin Hematol. 2009 Jan;16(1):3-8
19057198
Cell Death Differ. 2006 May;13(5):861-72
16470223
Oncogene. 2006 Oct 30;25(51):6781-99
17072328
Oncogene. 2006 Oct 30;25(51):6831-43
17072331
J Clin Invest. 2001 Jan;107(1):3-6
11134170
Cell Mol Life Sci. 2005 Aug;62(15):1682-91
15924263
J Invest Dermatol. 1996 Feb;106(2):368-76
8601744
Allergy. 2004 Jul;59(7):673-89
15180753
Curr Opin Genet Dev. 2001 Jun;11(3):300-6
11377967
Best Pract Res Clin Rheumatol. 2008 Oct;22(5):863-82
19028368
Mol Cell Neurosci. 2001 Feb;17(2):385-97
11178875
Vitam Horm. 2006;74:229-54
17027517
Curr Opin Cell Biol. 1999 Apr;11(2):226-32
10209157
Orphanet J Rare Dis. 2007 Sep 11;2:37
17848188
Drugs. 2009;69(7):859-88
19441872
Hautarzt. 2007 Feb;58(2):122, 124-7
17221241
J Allergy Clin Immunol. 2007 Jun;119(6):1291-300; quiz 1301-2
17399779
Am J Pathol. 1993 Sep;143(3):972-82
8362989
Trends Immunol. 2006 Sep;27(9):428-33
16861037
J Biol Chem. 2004 Apr 2;279(14):13677-88
14734551
Toxicol Pathol. 2004 Mar-Apr;32(2):181-91
15200156
Eur J Immunol. 2001 Mar;31(3):734-42
11241277
FASEB J. 2009 Sep;23(9):2796-802
19417085
Vet Pathol. 2006 Jul;43(4):401-23
16846982